Medical device maker GluSense (Rehovot, Israel), which is developing a long-lasting injectable glucose sensor for treating Type 1 diabetes, has received an investment from the JDRF T1D Fund, a venture philanthropy fund exclusively devoted to finding and funding early-stage Type 1 diabetes commercial programs.
Related: Light-driven biometric watches monitor glucose, pulse noninvasively
GluSense's Glyde CGM is a miniature long-term injectable glucose sensor. It is injected under the skin and expected to last for one year, providing continuous, accurate glucose measurements wirelessly to a convenient wearable device such as a watch. The injection of the device is minimally invasive and can be performed in a clinic using only local anesthesia. The T1D Fund's investment will be used to bring the device closer to the first in-human clinical trial, a key step in the commercialization process.
The device's technology uses a proprietary fluorescent glucose-sensitive biosensor that ensures accurate glucose measurement across the full physiological range, with enhanced accuracy at the medically important hypo-glucose range. The development ensures that the biosensor level in the implant is maintained stable over the long term using engineered live cells that constantly replenish the biosensor in the implant. The stable biosensor level enables calibration frequency to be significantly reduced, freeing users from the daily hassle of multiple calibration finger pricks.
GluSense is part of the Rainbow Medical innovation firm (Herzeliya Pituach, Israel), which seeds and grows companies developing breakthrough medical devices.
For more information, please visit www.glusensemedical.com and www.jdrf.org.